[ad_1]
Shares of Tempest Therapeutics Inc. TPST soared more than 1,900% on Wednesday after the company released study results for its investigational cancer treatment TPST-1120 in patients with liver cancer.
The drug candidate, in combination with the Roche Holding AG RHHBY treatments Tecentriq and Avastin, showed clinical superiority as a first-line treatment for unresectable or metastatic hepatocellular carcinoma, a common type of liver cancer, Tempest said in a release Wednesday.
Patients…
[ad_2]
Source link
